Omega 3 in Childhood Migraines: a Double Blind Randomized Clinical Trial

Afshin FAYYAZI, Ali KHAJEH, Ahad GHAZAVI, Mahsha SANGESTANI

Abstract


337

How to Cite This Article: Fayyazi A, Khajeh A, Ghazavi A, Sangestani M. Omega 3 in Childhood Migraines; A Double Blind Randomized Clinical Trial. Iran J Child Neurol. Winter 2016; 10(1):9-13.


Abstract

Objective

The effect of using omega-3 to prevent migraine attacks has been raised in recent studies. The majority of these studies have been conducted in adults.

Conversely, other studies have yet to confirm the effect of omega-3. The main purpose of this study was to assess the effects of omega-3 in the prevention of migraine attacks in children.

Materials & Methods

In this study, children aged 5–15 years with a diagnosis of migraine were randomly assigned to case and control groups. The case group was treated with sodium valproate and 1 g of omega-3; the control group was treated with sodium valproate and a placebo for 2 months. The severity of attacks was evaluated before and after the treatment using PedMIDAS and parental satisfaction (CGI) using a 7-point Likert scale.

Results

In this study, 12 cases and 13 controls were enrolled. The average number of headache attacks per month decreased significantly in both groups after starting the treatment but there was no significant difference between the two groups. The severity of attacks decreased significantly in both groups after

starting the treatment but it was not significant between them. Examination of the CGI average showed the average was 6.08 (SD = 0.52) in the case group and 6.07 (SD = 0.65) in the control group.

Conclusion

The present study indicated that omega-3 with a dose of 1 mg per day has no effect in reducing the severity and frequency of migraine attacks in children.

Sodium valproate was effective in reducing the frequency and severity of attacks.


Keywords


Children Migraine; Prevention; Treatment; Omega 3; Fish oil

Full Text:

PDF

231

References


Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S and et al .Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age. Pediatrics.2009; 123: 924-934.

Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx.2006; 3(2):181–191.

Pothmann R , Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005 Mar; 45(3):196-203.

Millichap JG and Yee MM. The Diet Factor in Pediatric and Adolescent Migraine. Pediatr Neurol. 2003 Jan; 28(1):9-15.

Drugs for preventing migraine headaches in children. Victor S, Ryan SW. Cochrane Database Syst Rev. 2003;(4):CD002761.

Damen L, Bruijn JK, Verhagen AP, Berger M Y, Passchier J and Koes BW.Symptomatic Treatment of Migraine in Children: A Systematic Review of Medication Trials.Pediatrics .2005;116:e295-e302.

Tonekaboni SH, Ghazavi A, Fayyazi A, Khajeh A, Taghdiri MM, Abdollah Gorji F, Azargashb E. Prophylaxis of Childhood Migraine: Topiramate Versus Propranolol. Iran J Child Neurol. 2013 winter; 7 (1):9-14.

Hope L O’Brien and Andrew D Hershey Vitamins and paediatric migraine:Riboflavin as a preventative medication. Cephalalgia. 2010; 30:1417-1418.

Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A .The Effects of Magnesium, l-Carnitine, and Concurrent Magnesium–l-Carnitine Supplementation in Migraine Prophylaxis.Biological Trace Element Research . 2012; 150: 42-48.

Tajmirriahi M, Sohelipour M, Basiri K, Shaygannejad V, Ghorbani A, Saadatnia M.The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial. Iran J Neurol. 2012; 11(1):21-4.

HAREL Z, GASCON G, RIGGS S, , VAZ R, BROWN W, AND EXIL G. Supplementation With Omega-3 Polyunsaturated Fatty Acids in the Management of Recurrent Migraines in Adolescents. Journal of Adolescent Health. 2002; 31:154–161.

Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, Launay JM,and et al.Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia. 2001 Oct; 21(8):818-22.

Mazza M, Pomponi M, Janiri L, Bria P, Mazza S .Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview.Progress in Neuro-Psychopharmacology & Biological Psychiatry . 2007; 31:12–26.

James S1, Montgomery P, Williams K.Omega-3 fatty acids supplementation for autism spectrum disorders (ASD).Cochrane Database Syst Rev. 2011 ; 9(11): CD007992.

Gillies D, Sinn JKh, Lad SS, Leach MJ, Ross MJ. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2012 Jul 11; 7:CD007986

Bloch MH, Qawasmi A.Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry.2011 Oct; 50(10):991-1000.




DOI: https://doi.org/10.22037/ijcn.v10i1.6132

Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 Iran Journal of Child Neurlogy